Browse by Academic Unit (A-Z)

Export as [feed] Atom [feed] RSS
Group by: Creators Name | Item Type
Number of items at this level: 60.

Article

Allan, J.M., Wild, C.P., Rollinson, S. et al. (7 more authors) (2001) Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapyinduced leukemia. Proceedings of the National Academy of Sciences, 98 (20). pp. 11592-11597. ISSN 0027-8424

Ashley, L, Jones, H, Forman, D et al. (5 more authors) (2011) Feasibility test of a UK-scalable electronic system for regular collection of patient-reported outcome measures and linkage with clinical cancer registry data: The electronic Patient-reported Outcomes from Cancer Survivors (ePOCS) system. BMC Medical Informatics and Decision Making, 11. 66. ISSN 1472-6947

Ashley, L, Jones, H, Thomas, J et al. (6 more authors) (2011) Integrating cancer survivors’ experiences into UK cancer registries: design and development of the ePOCS system (electronic Patient-reported Outcomes from Cancer Survivors). British Journal of Cancer, 105. S74-S81. ISSN 0007-0920

Brown, SR, Gregory, WM, Twelves, CJ et al. (5 more authors) (2011) Designing phase II trials in cancer: a systematic review and guidance. British Journal of Cancer, 105 (2). 194 - 199 . ISSN 1532-1827

Brüning-Richardson, A, Bond, J, Alsiary, R et al. (9 more authors) (2012) NuMA overexpression in epithelial ovarian cancer. PLoS One, 7 (6). ARTN e38945. e38945 - ?. ISSN 1932-6203

Chapman, MA, Sive, J, Ambrose, J et al. (27 more authors) (2018) RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature. Blood, 132 (20). pp. 2154-2165. ISSN 0006-4971

Cook, G, Iacobelli, S, van Biezen, A et al. (19 more authors) (2017) High dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: A retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation. Haematologica, 102. pp. 160-167. ISSN 0390-6078

Cook, G, Zweegman, S, Mateos, M-V et al. (2 more authors) (2018) A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma. Critical Reviews in Oncology/Hematology, 121. pp. 74-89. ISSN 1040-8428

Cortes, J, Hudgens, S, Twelves, C et al. (7 more authors) (2015) Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast cancer research and treatment, 154 (3). 509 - 520. ISSN 0167-6806

Costello, C, Davies, FE, Cook, G orcid.org/0000-0003-0223-3652 et al. (16 more authors) (2019) INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. Future Oncology, 15 (13). pp. 1411-1428. ISSN 1479-6694

Craven, I, Crellin, A, Cooper, R et al. (3 more authors) (2007) Preoperative radiotherapy combined with 5 days per week capecitabine chemotherapy in locally advanced rectal cancer. British Journal of Cancer, 97 (10). pp. 1333-1337. ISSN 0007-0920

Dimopoulos, MA, Kaufman, JL, White, D et al. (8 more authors) (2018) A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis. Clinical Lymphoma Myeloma and Leukemia, 18 (3). 163-173.e6. ISSN 2152-2650

Dimopoulos, MA, San-Miguel, J, Belch, A et al. (30 more authors) (2018) Daratumumab Plus Lenalidomide And Dexamethasone Versus Lenalidomide And Dexamethasone In Relapsed Or Refractory Multiple Myeloma: Updated Analysis Of POLLUX. Haematologica, 103 (12). pp. 2088-2096. ISSN 0390-6078

Donnelly, O, Vile, R, Pandha, H et al. (2 more authors) (2012) The hitchhiker's guide to virotherapy. Oncotarget, 3 (8). pp. 735-736. ISSN 1949-2553

El-Jawhari, JJ, El-Sherbiny, YM, Scott, GB et al. (8 more authors) (2014) Blocking oncogenic RAS enhances tumour cell surface MHC class I expression but does not alter susceptibility to cytotoxic lymphocytes. Molecular Immunology, 58 (2). 160 - 168. ISSN 0161-5890

Faivre-Finn, C, Snee, M, Ashcroft, L et al. (17 more authors) (2017) Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. The Lancet Oncology, 18 (8). pp. 1116-1125. ISSN 1470-2045

Feyler, S, Scott, GB, Parrish, C et al. (6 more authors) (2012) Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS ONE, 7 (5). e35981. ISSN 1932-6203

Garderet, L, Cook, G, Auner, HW et al. (12 more authors) (2016) Treatment options for relapse after autograft in multiple myeloma – report from an EBMT educational meeting. Leukemia & Lymphoma, 58 (4). pp. 797-808. ISSN 1042-8194

Hayes, J, Thygesen, H, Tumilson, C et al. (8 more authors) (2015) Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature. Molecular Oncology, 9 (3). 704 - 714. ISSN 1574-7891

Holmes, TD, Wilson, EB, Black, EVI et al. (5 more authors) (2014) Licensed human natural killer cells aid dendritic cell maturation via TNFSF14/LIGHT. Proceedings of the National Academy of Sciences of the United States of America (PNAS) , 111 (52). E5688-E5696. ISSN 1091-6490

Howell, D, Smith, A, Appleton, S et al. (5 more authors) (2017) Multiple myeloma: routes to diagnosis, clinical characteristics and survival - findings from a UK population-based study. British Journal of Haematology, 177 (1). pp. 67-71. ISSN 0007-1048

Howell, DA, Hart, RI, Smith, AG et al. (4 more authors) (2018) Myeloma: Patient accounts of their pathways to diagnosis. PLOS ONE, 13 (4). e0194788. ISSN 1932-6203

Ilett, E orcid.org/0000-0002-9875-0322, Kottke, T, Donnelly, O et al. (10 more authors) (2014) Cytokine Conditioning Enhances Systemic Delivery and Therapy of an Oncolytic Virus. Molecular Therapy, 22 (10). pp. 1851-1863. ISSN 1525-0016

Jones, JR, Cairns, DA, Gregory, WM orcid.org/0000-0003-2641-8416 et al. (19 more authors) (2016) Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer Journal, 6 (12). e506. ISSN 2044-5385

Jones, JR, Weinhold, N, Ashby, C et al. (19 more authors) (2019) Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. Haematologica, 104 (7). pp. 1440-1450. ISSN 0390-6078

Kane, E, Howell, D, Smith, A et al. (4 more authors) (2017) Emergency admission and survival from aggressive non-Hodgkin lymphoma: A report from the UK's population-based Haematological Malignancy Research Network. European Journal of Cancer, 78. pp. 53-60. ISSN 0959-8049

Kottke, T, Boisgerault, N, Diaz, RM et al. (12 more authors) (2013) Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence. Nature Medicine, 19. 1625 - 1631. ISSN 1078-8956

Kottke, T, Errington, F orcid.org/0000-0003-2155-534X, Pulido, J et al. (12 more authors) (2011) Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nature Medicine, 17 (7). pp. 854-859. ISSN 1078-8956

Langford, K.J., Askham, J.M., Lee, T. et al. (2 more authors) (2006) Examination of actin and microtubule dependent APC localisations in living mammalian cells. BMC Cell Biology, 7 (3). ISSN 1471-2121

Laycock, SD, Hulse, M, Scrase, CD et al. (7 more authors) (2015) Towards the production of radiotherapy treatment shells on 3D printers using data derived from DICOM CT and MRI: preclinical feasibility studies. Journal of Radiotherapy in Practice, 14 (01). 92 - 98. ISSN 1460-3969

Mateos, M-V, Spencer, A, Nooka, AK et al. (16 more authors) (2019) Daratumumab-Based Regimens Are Highly Effective And Well Tolerated In Relapsed Or Refractory Multiple Myeloma Regardless Of Patient Age: Subgroup Analysis Of The Phase 3 CASTOR And POLLUX Studies. Haematologica. ISSN 0390-6078

Maybury, B, Cook, G, Pratt, G et al. (2 more authors) (2016) Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma. Biology of Blood and Marrow Transplantation, 22 (11). pp. 1926-1937. ISSN 1083-8791

Merrick, AE, Errington, F orcid.org/0000-0003-2155-534X, Milward, K et al. (8 more authors) (2005) Immunosuppressive effects of radiation on human dendritic cells: reduced IL-12 production on activation and impairment of naïve T-cell priming. British Journal of Cancer, 92 (8). pp. 1450-1458. ISSN 0007-0920

Morden, JP, Alvarez, I, Bertelli, G et al. (18 more authors) (2017) Long-Term Follow-Up of the Intergroup Exemestane Study. Journal of Clinical Oncology, 35 (22). pp. 2507-2514. ISSN 0732-183X

Moreau, P, van de Donk, NWCJ, San Miguel, J et al. (17 more authors) (2016) Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma (vol 76, pg 853, 2016). Drugs, 76 (9). pp. 989-990. ISSN 0012-6667

Parrish, C, Morris, CTCM, Williams, CD et al. (13 more authors) (2016) Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial. Biology of Blood and Marrow Transplantation, 22 (6). pp. 1009-1016. ISSN 1083-8791

Pawlyn, C, Kaiser, MF, Heuck, C et al. (20 more authors) (2016) The spectrum and clinical impact of epigenetic modifier mutations in myeloma. Clinical Cancer Research, 22 (23). pp. 5783-5794. ISSN 1078-0432

Popat, R, Brown, SR, Flanagan, L et al. (9 more authors) (2016) Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. The Lancet Haematology, 3 (12). e572-e580. ISSN 2352-3026

Popat, R, Brown, SR, Flanagan, L et al. (10 more authors) (2019) Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi‐centre phase I/II Clinical Trial). British Journal of Haematology, 185 (3). pp. 573-578. ISSN 0007-1048

Poźniak, J, Nsengimana, J, Laye, JP et al. (15 more authors) (2019) Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma. Cancer Research, 79 (10). pp. 2684-2696. ISSN 0008-5472

Prestwich, RJD, Errington-Mais, F orcid.org/0000-0003-2155-534X, Harrington, KJ et al. (3 more authors) (2008) Oncolytic viruses: do they have a role in anti-cancer therapy? Clinical Medicine: Oncology, 2. pp. 83-96. ISSN 1177-9314

Royle, K-L, Gregory, WM orcid.org/0000-0003-2641-8416, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (8 more authors) (2018) Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study. British Journal of Haematology, 182 (6). pp. 816-829. ISSN 0007-1048

Schey, S, Brown, SR, Tillotson, A-L et al. (13 more authors) (2015) Bendamustine, thalidomide and dexamethasone combinationtherapy for relapsed/refractory myeloma patients: results ofthe MUKone randomized dose selection trial. British Journal of Haematology, 170 (3). pp. 336-348. ISSN 0007-1048

Schmitz, S, Maguire, Á, Morris, J et al. (11 more authors) (2018) The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma. BMC Medical Research Methodology, 18. 66. ISSN 1471-2288

Seligmann, JF, Wright-Hughes, A orcid.org/0000-0001-8839-6756, Pottinger, A et al. (10 more authors) (2020) Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with Trastuzumab (LANTERN): a Phase II Randomised Trial. Clinical Oncology, 32 (10). pp. 656-664. ISSN 0936-6555

Seymour, MT (2011) Sequential Chemotherapy for Colorectal Cancer. Lancet Oncology, 12. 1 - 2 (2). ISSN 0140-6736

Smith, MP, Wood, SL, Zougman, A et al. (7 more authors) (2011) A systematic analysis of the effects of increasing degrees of serum immunodepletion in terms of depth of coverage and other key aspects in top‐down and bottom‐up proteomic analyses. Proteomics, 11 (11). pp. 2222-2235. ISSN 1615-9853

Sturla, L-M, Merrick, AE and Burchill, SA (2003) FGFR3IIIS: a novel soluble FGFR3 spliced variant that modulates growth is frequently expressed in tumour cells. British Journal of Cancer, 89 (7). pp. 1276-1284. ISSN 0007-0920

Taylor, S, Harley, C, Campbell, LJ et al. (6 more authors) (2010) Discussion of emotional and social impact of cancer during outpatient oncology consultations. Psycho-Oncology, 20 (3). 242 - 251 . ISSN 1099-1611

Twigger, K, Roulstone, V, Kyula, J et al. (14 more authors) (2012) Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway. BMC Cancer, 12. 368. ISSN 1471-2407

Walker, BA, Boyle, EM, Wardell, CP et al. (24 more authors) (2015) Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. Journal of Clinical Oncology, 33 (33). pp. 3911-3920. ISSN 0732-183X

Walker, BA, Wardell, CP, Murison, A et al. (18 more authors) (2015) APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nature Communications, 6. ARTN 6997.

Westbury, CB, Freeman, A, Rashid, M et al. (3 more authors) (2014) Changes in mast cell number and stem cell factor expression in human skin after radiotherapy for breast cancer. Radiotherapy and Oncology, 111 (2). 206 - 211. ISSN 0167-8140

Westbury, CB, Haviland, J, Davies, S et al. (7 more authors) (2014) Cytokine levels as biomarkers of radiation fibrosis in patients treated with breast radiotherapy. Radiation Oncology, 9. 103. ISSN 1748-717X

Wilson, EB orcid.org/0000-0002-0441-728X, El-Jawhari, JJ orcid.org/0000-0002-0580-4492, Neilson, AL et al. (4 more authors) (2011) Human Tumour Immune Evasion via TGF-β Blocks NK Cell Activation but Not Survival Allowing Therapeutic Restoration of Anti-Tumour Activity. PLoS ONE, 6 (9). e22842. ISSN 1932-6203

Zougman, A and Banks, RE (2015) C-STrap Sample Preparation Method—In-Situ Cysteinyl Peptide Capture for Bottom-Up Proteomics Analysis in the STrap Format. PLoS ONE, 10 (9). 1 - 7 (7). ISSN 1932-6203

de Tute, RM, Rawstron, AC, Gregory, WM et al. (9 more authors) (2016) Minimal Residual Disease Following Autologous Stem Cell Transplant In Myeloma: Impact On Outcome Is Independent Of Induction Regimen. Haematologica, 101 (2). e69-e71. ISSN 0390-6078

van de Hulle, T, den Exter, PL, Planquette, B et al. (22 more authors) (2016) Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients. Journal of Thrombosis and Haemostasis, 14 (1). pp. 105-113. ISSN 1538-7933

Proceedings Paper

Alonso-Camino, V, Rajani, K, Kottke, T et al. (11 more authors) (2014) The Profile of Tumor Antigens Which Can Be Targeted By Immunotherapy Depends Upon the Tumor's Anatomical Site. In: Molecular Therapy. 7th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), 21-24 May 2014, Washington, DC, USA. Nature Publishing Group , S200-S200.

Walker, BA, Wardell, CP, Murison, A et al. (18 more authors) (2014) Apobec Family Mutational Signatures Are Associated with Poor Prognosis Translocations in Multiple Myeloma. In: BLOOD. 56th ASH Annual Meeting 2014, 06-09 Dec 2014, San Francisco, California, USA. American Society of Hematology .

This list was generated on Thu Mar 28 04:09:11 2024 GMT.